<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03704571</url>
  </required_header>
  <id_info>
    <org_study_id>2018SDU-QILU-G111</org_study_id>
    <nct_id>NCT03704571</nct_id>
  </id_info>
  <brief_title>A Predictive Model for Inadequate Bowel Preparation</brief_title>
  <official_title>A Predictive Model for Inadequate Bowel Preparation: Development and Validation With a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aimed to develop a predictive model of inadequate bowel preparation and to further
      validate it by a randomized controlled trial.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">August 30, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Bowel Preparation</measure>
    <time_frame>10 months</time_frame>
    <description>The quality of bowel preparation is evaluated using BBPS.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adenoma Detection Rate</measure>
    <time_frame>10 months</time_frame>
    <description>The proportion of patients from whom at least one adenoma can be detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Polyp Detection Rate</measure>
    <time_frame>10 months</time_frame>
    <description>The proportion of patients from whom at least one polyp can be detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>10 months</time_frame>
    <description>Including nausea, bloating, stomachache, vomiting, vertigo and belching and so on.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">429</enrollment>
  <condition>Bowel Preparation</condition>
  <arm_group>
    <arm_group_label>Tailored Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the tailored group, high-risk patients are instructed to drink the first 2 L of Polyethylene Glycol (PEG) at 19:00-21:00 hours on the day before colonoscopy at a rate of 250 ml every 15 min. On the day of the procedure, they take another 2 L PEG 4-6 h before colonoscopy. The low-risk patients were given a standard dose of 2 L PEG 4-6 h before colonoscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the control group, all the patients drink single dose of 2 l Polyethylene Glycol (PEG) 4-6 h before colonoscopy at a rate of 250 ml every 15 min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polyethylene Glycol</intervention_name>
    <description>In the Tailored group, high-risk people are given intensified bowel preparation regimens, low-risk people are given routine regimens.
In the control group, all the patients are given routine regimens.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Tailored Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-75 years undergoing colonoscopy

        Exclusion Criteria:

          -  known or suspected bowel obstruction, stricture or perforation

          -  compromised swallowing reflex or mental status

          -  severe chronic renal failure(creatinine clearance &lt; 30 ml/min)

          -  severe congestive heart failure (New York Heart Association class III or IV)

          -  uncontrolled hypertension (systolic blood pressure &gt; 170 mm Hg, diastolic blood
             pressure &gt; 100 mm Hg)

          -  dehydration

          -  disturbance of electrolytes

          -  pregnancy or lactation

          -  hemodynamically unstable

          -  unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 10, 2018</study_first_submitted>
  <study_first_submitted_qc>October 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2018</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>adenoma</keyword>
  <keyword>bowel preparation</keyword>
  <keyword>colonoscopy</keyword>
  <keyword>predictive model</keyword>
  <keyword>randomized controlled trial</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

